ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
Public ClinicalTrials.gov record NCT01418092. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b Randomized, Double-blind, Placebo-controlled, 12-week Study to Evaluate the Safety and Efficacy of ALKS 37 in Subjects With Opioid-induced Constipation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of ALKS 37 when administered daily to adults with OIC.
Study identification
- NCT ID
- NCT01418092
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 91 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2011
- Primary completion
- May 31, 2012
- Completion
- May 31, 2012
- Last update posted
- Aug 6, 2012
2011 – 2012
United States locations
- U.S. sites
- 13
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Anaheim | California | 92804 | — |
| Alkermes Investigational Site | Orange | California | 92868 | — |
| Alkermes Investigational Site | Daytona Beach | Florida | 32117 | — |
| Alkermes Investigational Site | Plantation | Florida | 33317 | — |
| Alkermes Investigational Site | Marietta | Georgia | 30060 | — |
| Alkermes Investigational Site | Indianapolis | Indiana | 46250 | — |
| Alkermes Investigational Site | Las Vegas | Nevada | 89119 | — |
| Alkermes Investigational Site | Willingboro | New Jersey | 08046 | — |
| Alkermes Investigational Site | Raleigh | North Carolina | 27612 | — |
| Alkermes Investigational Site | Philadelphia | Pennsylvania | 19139 | — |
| Alkermes Investigational Site | Austin | Texas | 78756 | — |
| Alkermes Investigational Site | Houston | Texas | 77098 | — |
| Alkermes Investigational Site | Bellevue | Washington | 98007 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01418092, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2012 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01418092 live on ClinicalTrials.gov.